NASDAQ:CLDX Celldex Therapeutics (CLDX) Stock Price, News & Analysis $28.74 -0.98 (-3.30%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Celldex Therapeutics Stock (NASDAQ:CLDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Celldex Therapeutics alerts:Sign Up Key Stats Today's Range$28.40▼$29.9350-Day Range$28.74▼$44.5452-Week Range$22.11▼$53.18Volume1.07 million shsAverage Volume855,729 shsMarket Capitalization$1.91 billionP/E RatioN/ADividend YieldN/APrice Target$62.25Consensus RatingModerate Buy Company OverviewCelldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Read More… Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Celldex Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks51st Percentile Overall ScoreCLDX MarketRank™: Celldex Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 624th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCelldex Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCelldex Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Celldex Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Celldex Therapeutics are expected to decrease in the coming year, from ($2.50) to ($3.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celldex Therapeutics is -10.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celldex Therapeutics is -10.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelldex Therapeutics has a P/B Ratio of 3.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Celldex Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.54% of the outstanding shares of Celldex Therapeutics have been sold short.Short Interest Ratio / Days to CoverCelldex Therapeutics has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Celldex Therapeutics has recently decreased by 1.19%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCelldex Therapeutics does not currently pay a dividend.Dividend GrowthCelldex Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.54% of the outstanding shares of Celldex Therapeutics have been sold short.Short Interest Ratio / Days to CoverCelldex Therapeutics has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Celldex Therapeutics has recently decreased by 1.19%, indicating that investor sentiment is improving. News and Social Media2.7 / 5News Sentiment0.87 News SentimentCelldex Therapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Celldex Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 10 people have searched for CLDX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Celldex Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Celldex Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.80% of the stock of Celldex Therapeutics is held by insiders.Read more about Celldex Therapeutics' insider trading history. Receive CLDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CLDX Stock News HeadlinesCelldex’s Barzolvolimab Outperforms Competitor in Chronic Inducible Urticaria Market, Justifying Buy RatingOctober 16 at 9:31 PM | markets.businessinsider.comCelldex Therapeutics, Inc. (CLDX): Hedge Funds’ Hidden Gem in Small-Cap StocksOctober 16 at 12:06 AM | insidermonkey.comHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.October 17, 2024 | Insiders Exposed (Ad)Citigroup Initiates Coverage of Celldex Therapeutics (CLDX) with Buy RecommendationOctober 8, 2024 | msn.comCelldex Therapeutics (NASDAQ:CLDX) Receives New Coverage from Analysts at CitigroupOctober 8, 2024 | americanbankingnews.comGoldman Sachs Initiates Coverage of Celldex Therapeutics (CLDX) with Neutral RecommendationOctober 2, 2024 | msn.comCelldex started by Goldman Sachs at neutral, lack of catalysts citedSeptember 30, 2024 | seekingalpha.comHold Rating on Celldex Therapeutics Amid Drug Development Prospects and Competitive ChallengesSeptember 30, 2024 | markets.businessinsider.comSee More Headlines CLDX Stock Analysis - Frequently Asked Questions How have CLDX shares performed this year? Celldex Therapeutics' stock was trading at $39.66 on January 1st, 2024. Since then, CLDX stock has decreased by 27.5% and is now trading at $28.74. View the best growth stocks for 2024 here. How were Celldex Therapeutics' earnings last quarter? Celldex Therapeutics, Inc. (NASDAQ:CLDX) posted its earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.05. The biopharmaceutical company earned $2.50 million during the quarter, compared to analyst estimates of $1.13 million. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative trailing twelve-month return on equity of 23.66%. When did Celldex Therapeutics' stock split? Celldex Therapeutics's stock reverse split on the morning of Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Celldex Therapeutics' major shareholders? Celldex Therapeutics' top institutional investors include Mirador Capital Partners LP (0.18%), SG Americas Securities LLC (0.03%), Creative Planning (0.02%) and Handelsbanken Fonder AB (0.02%). Insiders that own company stock include Samuel Bates Martin, Richard M Wright, Elizabeth Crowley, Margo Heath-Chiozzi, Diane C Young and Sarah Cavanaugh. View institutional ownership trends. How do I buy shares of Celldex Therapeutics? Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Celldex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Celldex Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), Alphabet (GOOG) and Visa (V). Company Calendar Last Earnings8/08/2024Today10/17/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryBiotechnology Current SymbolNASDAQ:CLDX CUSIP15117B10 CIK744218 Webwww.celldex.com Phone(908) 454-7120Fax908-454-1911Employees160Year Founded1983Price Target and Rating Average Stock Price Target$62.25 High Stock Price Target$90.00 Low Stock Price Target$37.00 Potential Upside/Downside+116.6%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-141,430,000.00 Net Margins-1,809.18% Pretax Margin-1,809.18% Return on Equity-23.66% Return on Assets-22.39% Debt Debt-to-Equity RatioN/A Current Ratio29.36 Quick Ratio29.36 Sales & Book Value Annual Sales$6.88 million Price / Sales276.91 Cash FlowN/A Price / Cash FlowN/A Book Value$9.08 per share Price / Book3.17Miscellaneous Outstanding Shares66,290,000Free Float63,769,000Market Cap$1.91 billion OptionableOptionable Beta1.55 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report This page (NASDAQ:CLDX) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.